Usages in wwPDB of concept: c_0652
nUsages: 762; SSE string: EEEEE
2of0:A     (ASN5) to    (GLY41)  X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 5  |   ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN 
2ohk:A     (ASN5) to    (GLY41)  X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 1- AMINO-ISOQUINOLINE  |   ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN 
2ohl:A     (ASN5) to    (ALA43)  X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 2- AMINOQUINOLINE  |   ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN 
2ohn:A     (ASN5) to    (GLY41)  X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 4- (4-FLUOROBENZYL)PIPERIDINE  |   ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN 
2ohp:A     (ASN5) to    (GLY41)  X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 3  |   ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN 
2ohq:A     (ASN5) to    (ALA43)  X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 4  |   ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, TRANSMEMBRANE, ZYMOGEN 
2oht:A     (ASN5) to    (GLY41)  X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 7  |   ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN 
2ohu:A     (ASN5) to    (GLY41)  X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8B  |   ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN 
2apr:A     (GLY4) to    (ALA44)  STRUCTURE AND REFINEMENT AT 1.8 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS  |   HYDROLASE (ASPARTIC PROTEINASE) 
2asi:A     (GLY5) to    (PRO47)  ASPARTIC PROTEINASE  |   HYDROLASE, ASPARTYL PROTEASE, GLYCOPROTEIN, ZYMOGEN 
3rth:A     (ASN5) to    (GLY41)  STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 6-(2-(3,3- DIMETHYLBUT-1-YNYL)PHENYL)QUINOLIN-2-AMINE  |   ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3rtm:A     (ASN5) to    (ALA43)  STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2- AMINOQUINOLIN-3-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE  |   ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3ru1:A     (ASN5) to    (ALA43)  STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2- AMINOQUINOLIN-3-YL)-N-(CYCLOHEXYLMETHYL)PROPANAMIDE  |   ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3rvi:A     (ASN5) to    (GLY41)  STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 2-((2-AMINO-6-O- TOLYLQUINOLIN-3-YL)METHYL)-N-(CYCLOHEXYLMETHYL)PENTANAMIDE  |   ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4h3f:A    (ASN66) to   (GLY102)  STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(6-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[3,4-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE  |   BACE1, ALZHEIMERS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4h3g:A    (ASN66) to   (GLY102)  STRUCTURE OF BACE BOUND TO 2-((7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2- YL)-2-IMINO-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[3,4-D]PYRIMIDIN-6(2H)- YL)NICOTINONITRILE  |   BACE1, ALZHEIMERS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1apw:E     (ALA1) to    (PHE42)  CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND DIFLUOROSTATONE-CONTAINING PEPTIDES  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4wy1:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO COMPOUND 24B  |   BETA SECRETASE BACE PROTEASE 
4wy6:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO COMPOUND 36  |   BACE BETA SECRETASE PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2bju:A     (ASN3) to    (PRO43)  PLASMEPSIN II COMPLEXED WITH A HIGHLY ACTIVE ACHIRAL INHIBITOR  |   PLASMEPSIN, ASPARTIC PROTEINASE, DRUG DESIGN, MALARIA, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, SIGNAL, ZYMOGEN 
2bkt:A     (THR2) to    (PRO42)  CRYSTAL STRUCTURE OF RENIN-PF00257567 COMPLEX  |   RENIN, ASPARTYL PROTEASE, HYDROLASE 
2bkt:B     (THR2) to    (PRO42)  CRYSTAL STRUCTURE OF RENIN-PF00257567 COMPLEX  |   RENIN, ASPARTYL PROTEASE, HYDROLASE 
1od1:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN PD135,040 COMPLEX  |   ACID PROTEINASE, INHIBITOR, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1oew:A     (SER1) to    (PHE44)  ATOMIC RESOLUTION STRUCTURE OF NATIVE ENDOTHIAPEPSIN  |   HYDROLASE, ASPARTIC PROTEINASE MECHANISM, ATOMIC RESOLUTION, SUCCINIMIDE, ANISOTROPIC REFINEMENT 
1oex:A     (SER1) to    (PHE44)  ATOMIC RESOLUTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A HYDROXYETHYLENE TRANSITION STATE ANALOGUE INHIBITOR H261  |   ASPARTIC PROTEINASE MECHANISM, ATOMIC RESOLUTION, SUCCINIMIDE, ANISOTROPIC REFINEMENT, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4hzt:A    (ASN66) to   (GLY102)  STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES  |   ASPARTIC PROTEASE, HYDROLYSIS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4i0o:A   (HIS268) to   (TYR321)  NUCLEOPORIN ELYS (AA1-494), MUS MUSCULUS  |   BETA PROPELLER, STRUCTURAL PROTEIN, NUCLEAR PORE COMPLEX, WD40 REPEAT, MRNA TRANSPORT 
3skf:B     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3S)-3-(ACETYLAMINO)-3-(BUTAN-2-YL)-2-OXOPYRROLIDIN-1- YL)-N-((2S,3R)-3-HYDROXY-4-((3-METHOXYBENZYL)AMINO)-1-PHENYLBUTAN-2- YL)-4-PHENYLBUTANAMIDE  |   ALZHEIMER'S DISEASE, BACE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3fns:A     (PHE1) to    (PRO41)  CRYSTAL STRUCTURE OF HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE, HAP, PLASMEPSIN, ASPARTIC PROTEASE, HORMONE, HYDROLASE 
3fns:B     (PHE1) to    (PRO41)  CRYSTAL STRUCTURE OF HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE, HAP, PLASMEPSIN, ASPARTIC PROTEASE, HORMONE, HYDROLASE 
3fnu:A     (ASP2) to    (PRO41)  CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE,HYDROLASE, PLASMEPSIN, ASPARTIC PROTEASE, KNI, KNI-10006, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3fnu:B     (ASP2) to    (PRO41)  CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE,HYDROLASE, PLASMEPSIN, ASPARTIC PROTEASE, KNI, KNI-10006, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3fnu:C     (PHE1) to    (PRO41)  CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE,HYDROLASE, PLASMEPSIN, ASPARTIC PROTEASE, KNI, KNI-10006, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3fnu:D     (PHE1) to    (PRO41)  CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE,HYDROLASE, PLASMEPSIN, ASPARTIC PROTEASE, KNI, KNI-10006, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1cms:A     (GLU2) to    (PRO43)  THE THREE-DIMENSIONAL STRUCTURE OF RECOMBINANT BOVINE CHYMOSIN AT 2.3 ANGSTROMS RESOLUTION  |   HYDROLASE(ACID PROTEINASE) 
1czi:E    (GLU-1) to    (PRO41)  CHYMOSIN COMPLEX WITH THE INHIBITOR CP-113972  |   ACID PROTEINASE, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1dpj:A     (HIS2) to    (PRO41)  THE STRUCTURE OF PROTEINASE A COMPLEXED WITH IA3 PEPTIDE INHIBITOR  |   PROTEINASE A, IA3 PEPTIDE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4xx3:A    (ASN71) to   (PRO113)  RENIN IN COMPLEX WITH (S)-1-(3-(BENZYLCARBAMOYL)BENZYL)-4-ISOPROPYL-4- METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM  |   ANIMALS, ANTIHYPERTENSIVE AGENTS, BLOOD PRESSURE, DRUG DESIGN, ENZYME INHIBITORS, MODELS, MOLECULAR, PROTEIN CONFORMATION, RATS, RENIN, STRUCTURE-ACTIVITY RELATIONSHIP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4xx3:B    (ASN71) to   (PRO113)  RENIN IN COMPLEX WITH (S)-1-(3-(BENZYLCARBAMOYL)BENZYL)-4-ISOPROPYL-4- METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM  |   ANIMALS, ANTIHYPERTENSIVE AGENTS, BLOOD PRESSURE, DRUG DESIGN, ENZYME INHIBITORS, MODELS, MOLECULAR, PROTEIN CONFORMATION, RATS, RENIN, STRUCTURE-ACTIVITY RELATIONSHIP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4xx4:A    (ASN71) to   (PRO113)  RENIN IN COMPLEX WITH (4S)-4-ISOPROPYL-4-METHYL-6-OXO-1-(3-(2-OXO-4- PHENYLPYRROLIDIN-1-YL)BENZYL)TETRAHYDROPYRIMIDIN-2(1H)-IMINIUM  |   ANIMALS, ANTIHYPERTENSIVE AGENTS, BLOOD PRESSURE, DRUG DESIGN, ENZYME INHIBITORS, MODELS, MOLECULAR, PROTEIN CONFORMATION, RENIN, STRUCTURE-ACTIVITY RELATIONSHIP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4xx4:B    (ASN71) to   (PRO113)  RENIN IN COMPLEX WITH (4S)-4-ISOPROPYL-4-METHYL-6-OXO-1-(3-(2-OXO-4- PHENYLPYRROLIDIN-1-YL)BENZYL)TETRAHYDROPYRIMIDIN-2(1H)-IMINIUM  |   ANIMALS, ANTIHYPERTENSIVE AGENTS, BLOOD PRESSURE, DRUG DESIGN, ENZYME INHIBITORS, MODELS, MOLECULAR, PROTEIN CONFORMATION, RENIN, STRUCTURE-ACTIVITY RELATIONSHIP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4xxs:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF BACE1 WITH A PYRAZOLE-SUBSTITUTED TETRAHYDROPYRAN THIOAMIDINE  |   AMYLOID PRECURSOR PROTEIN SECRETASES, ASPARTIC ACID ENDOPEPTIDASES, DRUG DESIGN, STRUCTURE-ACTIVITY RELATIONSHIP 
1ppl:E     (ALA1) to    (PHE42)  CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3t7x:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1psa:A     (ILE1) to    (PRO41)  STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1psa:B     (ILE1) to    (PRO41)  STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1psn:A     (ASP2) to    (PRO41)  THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN  |   HYDROLASE (ACID PROTEINASE) 
1pso:E     (VAL1) to    (PRO41)  THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4y36:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 4  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4j0t:A    (ASN66) to   (GLY102)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-ETHOXY-PYRIDINE-2- CARBOXYLIC ACID [3-((R)-2-AMINO-5,5-DIFLUORO-4-METHYL-5,6-DIHYDRO-4H- [1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE  |   POTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4y35:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 290  |   FAGMENT SCREENING, HYDROLASE, INHIBITION 
4y37:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGEMENT 305  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y38:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B29  |   FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE 
4y3a:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 181  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4j0y:A    (ASN66) to   (GLY102)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R,5S)-2-AMINO-5-FLUORO-4-METHYL-5,6-DIHYDRO-4H- [1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE  |   PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4j0z:A    (ASN66) to   (GLY102)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S,5R)-2-AMINO-5-FLUORO-4-FLUOROMETHYL-5,6- DIHYDRO-4H-[1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE  |   PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4y3d:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 321  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y3e:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 5  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4j1c:A    (ASN66) to   (GLY102)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((S)-2-AMINO-5,5-DIFLUORO-4-FLUOROMETHYL-5,6- DIHYDRO-4H-[1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE  |   PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4j1e:A    (ASN66) to   (GLY102)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S,6S)-2-AMINO-4-FLUOROMETHYL-6-TRIFLUOROMETHYL- 5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE  |   PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4j1f:A    (ASN66) to   (GLY102)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S,6S)-2-AMINO-4-METHYL-6-TRIFLUOROMETHYL-5,6- DIHYDRO-4H-[1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE  |   PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4y3h:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 189  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y3j:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B30  |   FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE 
4j1i:A    (ASN66) to   (GLY102)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R,5R,6R)-2-AMINO-5-FLUORO-4-METHYL-6- TRIFLUOROMETHYL-5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]- AMIDE  |   PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4y3l:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 205  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y3m:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 103  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y3n:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 273  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y3t:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 207  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y3p:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 17  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y3q:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 109  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y3r:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 306  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y3s:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 266  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y3w:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 35  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y3x:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 171  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y3y:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B42  |   FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE 
4y43:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 42  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y44:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 164  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y45:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 291  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y48:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B50  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y47:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 162  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y4b:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 323  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y4a:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 286  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y4c:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 158  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y4d:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B51  |   FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE 
4y4e:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 131  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y4j:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B97  |   FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE 
4y4t:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 114  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y4w:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 125  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y4z:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 73  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y51:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 52  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y53:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 54  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y54:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 56  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y56:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 58  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y57:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 63  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y58:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 260  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y5a:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 206  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y5b:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 261  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y5c:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 267  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y5e:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 268  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y5g:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 272  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y5l:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN ITS APO FORM  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y5k:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 274  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y5m:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 328  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y5n:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 337  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y5p:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 338  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y6m:A     (ASN3) to    (PRO43)  STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418  |   PLASMEPSIN II HYDROXYETHYLAMINE-BASD INHIBITOR, HYDROLASE 
3gw5:B    (ILE11) to    (PRO47)  CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH A NOVEL INHIBITOR  |   RENIN, ASPARTATE PROTEASE, HYPERTENSION, RENIN EXPRESSION, RENIN INHIBITOR, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, SECRETED, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3tne:B     (ASP1) to    (VAL41)  THE CRYSTAL STRUCTURE OF PROTEASE SAPP1P FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH THE HIV PROTEASE INHIBITOR RITONAVIR  |   ASPARTIC ACID ENDOPEPTIDASES, CATALYTIC DOMAIN, RITONAVIR, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
4ya8:B     (ASN3) to    (PRO43)  STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394  |   PLASMEPSIN II, MALARIA, INHIBITOR, HYDROLASE 
4ya8:C     (ASN3) to    (PRO43)  STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394  |   PLASMEPSIN II, MALARIA, INHIBITOR, HYDROLASE 
4ya8:D     (ASN3) to    (PRO43)  STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394  |   PLASMEPSIN II, MALARIA, INHIBITOR, HYDROLASE 
4yck:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 211  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
3tpr:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF BACE1 COMPLEXED WITH AN INHIBITOR  |   MEMAPSIN 2, PROTEASE, BETA-SECRETASE 1, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4yct:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 216  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4yd3:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 224  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4yd5:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 236  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4yd6:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 240  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
2ren:A     (THR6) to    (PRO47)  STRUCTURE OF RECOMBINANT HUMAN RENIN, A TARGET FOR CARDIOVASCULAR- ACTIVE DRUGS, AT 2.5 ANGSTROMS RESOLUTION  |   HYDROLASE(ACID PROTEINASE) 
3h0b:B     (ASN5) to    (GLY41)  DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS  |   ASPARTYL PROTEASE, ALTERNATIVE SPLICING, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
3h0b:C     (ASN5) to    (GLY41)  DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS  |   ASPARTYL PROTEASE, ALTERNATIVE SPLICING, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
1epo:E    (SER-2) to    (PHE41)  ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH CP-81,282 (MOR PHE NLE CHF NME)  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2rmp:A     (GLY5) to    (PRO47)  RMP-PEPSTATIN A COMPLEX  |   ASPARTIC PROTEINASE, PEPSTATIN A, ASPARTYL PROTEASE-PEPTIDE COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4jp9:A    (ASN53) to    (GLY89)  SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS  |   ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4jpc:A    (ASN53) to    (GLY89)  SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS  |   ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4jpe:A    (ASN53) to    (GLY89)  SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS  |   ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1qrp:E     (ASP2) to    (PRO41)  HUMAN PEPSIN 3A IN COMPLEX WITH A PHOSPHONATE INHIBITOR IVA-VAL-VAL- LEU(P)-(O)PHE-ALA-ALA-OME  |   ASPARTIC PROTEINASE, PHOSPHONATE INHIBITOR, TRANSITION STATE ANALOGUE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1f34:A     (GLY2) to    (PRO41)  CRYSTAL STRUCTURE OF ASCARIS PEPSIN INHIBITOR-3 BOUND TO PORCINE PEPSIN  |   PROTEINASE-INHIBITOR COMPLEX, HYDROLASE/HYDROLASE INHIBITOR COMPLEX 
3u6a:B     (ASN5) to    (GLY41)  RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS  |   BETA-SITE APP CLEAVING ENZYME 1, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3u6a:C     (ASN5) to    (GLY41)  RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS  |   BETA-SITE APP CLEAVING ENZYME 1, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1fbn:A     (GLU2) to    (ARG50)  CRYSTAL STRUCTURE OF A FIBRILLARIN HOMOLOGUE FROM METHANOCOCCUS JANNASCHII, A HYPERTHERMOPHILE, AT 1.6 A  |   FIBRILLARIN, MJ PROTEINS, RIBOSOMAL RNA PROCESSING, SNORNP, STRUCTURAL GENOMICS, BSGC STRUCTURE FUNDED BY NIH, PROTEIN STRUCTURE INITIATIVE, PSI, BERKELEY STRUCTURAL GENOMICS CENTER, RIBOSOME 
3u75:C   (ALA230) to   (ASP279)  STRUCTURE OF E230A-FRUCTOFURANOSIDASE FROM SCHWANNIOMYCES OCCIDENTALIS COMPLEXED WITH FRUCTOSYLNYSTOSE  |   GLYCOSIDASE GH32, BETA-PROPELLER, HYDROLASE, CARBOHYDRATE/SUGAR BINDING, GLYCOSYLATIONS 
2v00:A     (SER1) to    (PHE44)  X-RAY CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH COMPOUND 1  |   FRAGMENT HIT, B- SECRETASE, ENDOTHIAPEPSIN, BACE, ZYMOGEN, PROTEASE, HYDROLASE, ISOCYTOSINE, ALZHEIMER'S DISEASE, FRAGMENT-BASED LEAD GENERATION, ASPARTYL PROTEASE, SURROGATE PROTEIN 
2v11:C     (THR6) to    (PRO47)  CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 6  |   GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES 
2v12:C     (THR6) to    (PRO47)  CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 8  |   GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES 
2er7:E    (SER-2) to    (PHE41)  X-RAY ANALYSES OF ASPARTIC PROTEINASES.III. THREE-DIMENSIONAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH A TRANSITION-STATE ISOSTERE INHIBITOR OF RENIN AT 1.6 ANGSTROMS RESOLUTION  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX, ACID PROTEINASE 
3udj:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF BACE WITH COMPOUND 5  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3udq:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF BACE WITH COMPOUND 13  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3ugg:B   (CYS212) to   (PRO265)  CRYSTAL STRUCTURE OF A 6-SST/6-SFT FROM PACHYSANDRA TERMINALIS IN COMPLEX WITH 1-KESTOSE  |   FRUCTOSYLTRANSFERASE, GLYCOSIDE HYDROLASE FAMILY 32, TRANSFERASE 
3ugh:B   (CYS212) to   (PRO265)  CRYSTAL STRUCTURE OF A 6-SST/6-SFT FROM PACHYSANDRA TERMINALIS IN COMPLEX WITH 6-KESTOSE  |   FRUCTOSYLTRANSFERASE, GLYCOSIDE HYDROLASE FAMILY 32, TRANSFERASE 
2va5:A     (ASN5) to    (GLY41)  X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8C  |   BASE, ZYMOGEN, PROTEASE, MEMBRANE, HYDROLASE, ALZHEIMER'S DISEASE, ALTERNATIVE SPLICING, MEMAPSIN 2, GLYCOPROTEIN, TRANSMEMBRANE, BETA-SECRETASE, ASPARTYL PROTEASE, ASPARTIC PROTEASE 
4ke0:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 13  |   ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, AMYLOID PRECURSOR PROTEIN (APP), HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4ke0:B     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 13  |   ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, AMYLOID PRECURSOR PROTEIN (APP), HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1g8s:A     (ASP3) to    (ARG50)  METHANOCOCCUS JANNASCHII FIBRILLARIN PRE-RRNA PROCESSING PROTEIN  |   RRNA PROCESSING; RNA BINDING, RNA BINDING PROTEIN 
3urj:A     (SER1) to    (PHE44)  TYPE IV NATIVE ENDOTHIAPEPSIN  |   ASPARTIC PROTEINASE, PROTEOLYSIS, SECRETED., HYDROLASE 
2viy:A    (ASN66) to   (GLY102)  HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(PENTYLSULFONYL)BENZAMIDE  |   ALTERNATIVE SPLICING, BETA-SITE APP CLEAVING ENZYME, BETA-SECRETASE, ASPARTYL PROTEASE, ASP-2, BACE-1, ZYMOGEN, PROTEASE, MEMBRANE, HYDROLASE, MEMAPSIN-2, GLYCOPROTEIN, TRANSMEMBRANE 
2viz:A    (ASN66) to   (GLY102)  HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(2-OXO-1-PYRROLIDINYL)-5-(PROPYLOXY) BENZAMIDE  |   ALTERNATIVE SPLICING, BETA-SITE APP CLEAVING ENZYME, BETA-SECRETASE, ASPARTYL PROTEASE, ASP-2, BACE-1, ZYMOGEN, PROTEASE, MEMBRANE, HYDROLASE, MEMAPSIN-2, GLYCOPROTEIN, TRANSMEMBRANE 
2vj6:A    (ASN66) to   (GLY102)  HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1- PYRROLIDINYL)BENZAMIDE  |   MEMBRANE, HYDROLASE, MEMAPSIN-2, GLYCOPROTEIN 
2vj7:A    (ASN66) to   (GLY102)  HUMAN BACE-1 IN COMPLEX WITH 3-(ETHYLAMINO)-N-((1S,2R)-2- HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL) METHYL)AMINO)PROPYL)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE  |   ALTERNATIVE SPLICING, BETA-SITE APP CLEAVING ENZYME, BETA-SECRETASE, ASPARTYL PROTEASE, ASP-2, BACE-1, ZYMOGEN, PROTEASE, MEMBRANE, HYDROLASE, MEMAPSIN-2, GLYCOPROTEIN, TRANSMEMBRANE 
3hvg:B     (ASN5) to    (GLY41)  STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0  |   PROTEASE, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, AMYLOID PRECURSOR PROTEIN SECRETASES, ASPARTIC ENDOPEPTIDASES, FRAGMENT- BASED DRUG DESIGN, FLUORESCENCE POLARISATION, DISULFIDE BOND, TRANSMEMBRANE, ZYMOGEN 
4zea:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B91  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
1gkt:A     (SER1) to    (PHE44)  NEUTRON LAUE DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH TRANSITION STATE ANALOGUE INHIBITOR H261  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX, PROTEASE-INHIBITOR, ASPARTIC PROTEINASE, HYDROLYSIS, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
2vnn:A    (ASN66) to   (GLY102)  HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S,2R)-2-HYDROXY-1- (PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-1-METHYL-3,4-DIHYDRO-1H-(1,2,5)THIADIAZEPINO(3,4,5- HI)INDOLE-9-CARBOXAMIDE 2,2-DIOXIDE  |   HYDROLASE, ALTERNATIVE SPLICING, BETA-SITE APP CLEAVING ENZYME, BETA-SECRETASE, ASPARTYL PROTEASE, ASP-2, BACE-1, ZYMOGEN, PROTEASE, MEMBRANE, MEMAPSIN-2, GLYCOPROTEIN, TRANSMEMBRANE 
2g1s:A     (SER3) to    (PRO42)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g1s:B     (SER3) to    (PRO42)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g1y:A     (SER3) to    (PRO42)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g24:B     (SER3) to    (PRO42)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g26:A     (SER3) to    (PRO42)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
1sme:B     (SER2) to    (PRO43)  PLASMEPSIN II, A HEMOGLOBIN-DEGRADING ENZYME FROM PLASMODIUM FALCIPARUM, IN COMPLEX WITH PEPSTATIN A  |   ASPARTYL PROTEINASE, ASPARTIC PROTEINASE, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1smr:A     (LEU0) to    (PRO41)  THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN  |   ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1smr:C     (LEU0) to    (PRO41)  THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN  |   ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1smr:E     (LEU0) to    (PRO41)  THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN  |   ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1smr:G     (LEU0) to    (PRO41)  THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN  |   ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2vs2:A     (SER1) to    (PHE44)  NEUTRON DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.  |   ACID PROTEINASE, ASPARTYL PROTEASE, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4kup:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH 20MM ACYLHYDRAZONE INHIBITOR  |   HYDROLASE, ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1gvt:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN COMPLEX WITH CP-80,794  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX, ASPARTIC PROTEINASE MECHANISM, TETRAHEDRAL INTERMEDIATE, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
1gvu:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN COMPLEX WITH H189  |   HYDROLASE, ASPARTIC PROTEINASE MECHANISM, ATOMIC RESOLUTION, Z TETRAHEDRAL INTERMEDIATE, ANISOTROPIC REFINEMENT, ASPARTYL P, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1gvv:A     (SER1) to    (PHE44)  FIVE ATOMIC RESOLUTION STRUCTURES OF ENDOTHIAPEPSIN INHIBITOR COMPLEXES; IMPLICATIONS FOR THE ASPARTIC PROTEINASE MECHANISM  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX, ASPARTIC PROTEINASE MECHANISM, Z TETRAHEDRAL INTERMEDIATE, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
1gvx:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN COMPLEXED WITH H256  |   HYDROLASE, ASPARTIC PROTEINASE MECHANISM, TETRAHEDRAL INTERMEDIATE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3vf3:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BQQ711  |   STRUCTURE-BASED DRUG DESIGN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4l6b:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH THIOPHEN-BASED INHIBITOR SAP128  |   ASPARTATE PROTEASE, INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4l7g:A     (ASN5) to    (GLY41)  DIETHYLAMINOSULFUR TRIFLUORIDE-MEDIATED INTRAMOLECULAR CYCLIZATION OF 2-HYDROXY-BENZYLUREAS TO FUSED BICYCLIC AMINOOXAZOLINE COMPOUNDS AND EVALUATION OF THEIR BIOCHEMICAL ACTIVITY AGAINST BETA-SECRETASE-1 (BACE1)  |   ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4lap:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH THIOPHEN-BASED INHIBITOR SAP114  |   ASPARTATE PROTEASE, INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4lbt:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH 100MM ACYLHYDRAZONE INHIBITOR  |   HYDROLASE, ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4lc7:A    (ASN66) to   (GLY102)  AMINOOXAZOLINE INHIBITOR OF BACE-1  |   ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4zsr:A     (ASN5) to    (GLY41)  BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR  |   ASPARTYL, PROTEASE, BETA-SECRETASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4zsr:B     (ASN5) to    (GLY41)  BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR  |   ASPARTYL, PROTEASE, BETA-SECRETASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3ilf:A   (LYS106) to   (VAL142)  CRYSTAL STRUCTURE OF PORPHYRANASE A (PORA) IN COMPLEX WITH NEO- PORPHYROTETRAOSE  |   GLYCOSIDE HYDROLASE FAMILY GH16, BETA-SANDWICH FOLD, JELLY ROLL, HYDROLASE-CARBOHYDRATE COMPLEX 
3inf:A    (ASN67) to   (ALA105)  BACE1 WITH THE AMINOHYDANTOIN COMPOUND 37  |   BACE1, INHIBITOR, XRAY, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
4lhh:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH 2MM ACYLHYDRAZONE INHIBITOR  |   HYDROLASE, ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3ivh:A    (ASN66) to   (GLY102)  DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS  |   ASPARTYL PROTEASE, BACE-1 INHIBITORS, ALZHEIMER'S DISEASE, STRUCTURE- BASED DRUG DESIGN, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
2web:A     (ALA1) to    (PHE42)  ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-FORMYL)-L- VALYL)AMINO-2-(2-NAPHTHYL)ETHYL)HYDROXYPHOSPHINYLOXY]-3- PHENYLPROPANOATE, SODIUM SALT  |   PENICILLOPEPSIN, PHOSPHONATE INHIBITOR, HYDROLASE 
2wf0:A    (ASN66) to   (GLY102)  HUMAN BACE-1 IN COMPLEX WITH 4-ETHYL-N-((1S,2R)-2-HYDROXY-1- (PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-8-(2-OXO-1-PYRROLIDINYL)-6-QUINOLINECARBOXAMIDE  |   HYDROLASE, MEMAPSIN-2, POLYMORPHISM, GLYCOPROTEIN, ASP-2, BACE-1, ZYMOGEN, PROTEASE, MEMBRANE, TRANSMEMBRANE, BETA-SECRETASE, DISULFIDE BOND, ASPARTYL PROTEASE, ALTERNATIVE SPLICING, BETA-SITE APP CLEAVING ENZYME 
2wf1:A    (ASN66) to   (GLY102)  HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S,2R)-2-HYDROXY-3- (((3-(METHYLOXY)PHENYL(METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-3,4-DIHYDRO-1H-(1,2,5)THIADIAZEPINO(3,4,5- HI)INDOLE-9-CARBOXAMIDE 2,2-DIOXIDE  |   HYDROLASE, MEMAPSIN-2, POLYMORPHISM, GLYCOPROTEIN, ASP-2, BACE-1, ZYMOGEN, PROTEASE, MEMBRANE, TRANSMEMBRANE, BETA-SECRETASE, DISULFIDE BOND, ASPARTYL PROTEASE, ALTERNATIVE SPLICING, BETA-SITE APP CLEAVING ENZYME 
3ixj:A    (ASN53) to    (GLY89)  CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR  |   BACE, BETA SECRETASE-1, INHIBITOR, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN, DISULFIDE BOND, POLYMORPHISM, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3ixj:C    (ASN53) to    (GLY89)  CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR  |   BACE, BETA SECRETASE-1, INHIBITOR, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN, DISULFIDE BOND, POLYMORPHISM, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2wf4:A    (ASN66) to   (GLY102)  HUMAN BACE-1 IN COMPLEX WITH 6-ETHYL-1-METHYL-N-((1S)-2-OXO- 1-(PHENYLMETHYL)-3-(TETRAHYDRO-2H-PYRAN-4-YLAMINO)PROPYL)- 1,3,4,6-TETRAHYDRO(1,2)THIAZEPINO(5,4,3-CD)INDOLE-8- CARBOXAMIDE 2,2-DIOXIDE  |   HYDROLASE, MEMAPSIN-2, POLYMORPHISM, GLYCOPROTEIN, ASP-2, BACE-1, ZYMOGEN, PROTEASE, MEMBRANE, TRANSMEMBRANE, BETA-SECRETASE, DISULFIDE BOND, ASPARTYL PROTEASE, ALTERNATIVE SPLICING, BETA-SITE APP CLEAVING ENZYME 
3vsx:A    (ILE11) to    (PRO47)  HUMAN RENIN IN COMPLEX WITH COMPOUND 18  |   RAS, HYPERTENSION, INHIBITOR, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3vv6:A     (ASN5) to    (ALA43)  CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-3-METHYL-6- ((1S, 2R)-2-PHENYLCYCLOPROPYL)PYRIMIDIN-4(3H)-ONE  |   ASPARTYL PROTEASE, BACE, BATA SECRETASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3vv7:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-6-((1S,2R)- 2-(3'-METHOXYBIPHENYL-3-YL)CYCLOPROPYL)-3-METHYLPYRIMIDIN-4(3H)-ONE  |   ASPARTYL PROTEASE, BASE, BETA-SECRETASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3vyf:A    (ILE11) to    (PRO47)  HUMAN RENIN IN COMPLEX WITH INHIBITOR 9  |   ASPARTYL PROTEASE, RAS, HYPERTENSION, INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3vyf:B    (ILE11) to    (PRO47)  HUMAN RENIN IN COMPLEX WITH INHIBITOR 9  |   ASPARTYL PROTEASE, RAS, HYPERTENSION, INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1uh7:A     (GLY4) to    (ALA44)  CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 4.6  |   PEPSIN, ASPARTIC PROTEINASE, HYDROLASE 
1uh8:A     (GLY4) to    (ALA44)  CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 8.0  |   PEPSIN, ASPARTIC PROTEINASE, HYDROLASE 
2i4q:A     (ASN0) to    (PRO42)  HUMAN RENIN/PF02342674 COMPLEX  |   RENIN INHIBITOR, PROTEIN-LIGAND COMPLEX, HYDROLASE 
2igx:A     (ASN3) to    (PRO43)  ACHIRAL, CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II  |   ACHIRAL INHIBITOR, HYDROLASE 
2igy:A     (ASN3) to    (PRO43)  ACHIRAL, CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II  |   ACHIRAL INHIBITOR, HYDROLASE 
2igy:B     (ASN3) to    (PRO43)  ACHIRAL, CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II  |   ACHIRAL INHIBITOR, HYDROLASE 
2iko:A     (ASN0) to    (PRO42)  CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR  |   RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE 
2iko:B     (ASN0) to    (PRO42)  CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR  |   RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE 
2iku:A     (ILE6) to    (PRO42)  CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITORS  |   RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE 
2iku:B     (ASN0) to    (PRO42)  CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITORS  |   RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE 
2il2:A     (ASN0) to    (PRO42)  CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR  |   RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE 
2il2:B     (ASN0) to    (PRO42)  CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR  |   RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE 
5apr:E     (GLY4) to    (ALA44)  STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2xfi:A    (ASN66) to   (GLY102)  HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-((METHYLSULFONYL)(PHENYL)AMINO) BENZAMIDE  |   HYDROLASE, PROTEASE, ZYMOGEN 
2xfj:A    (ASN66) to   (GLY102)  HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1- PYRROLIDINYL)BENZAMIDE  |   ZYMOGEN, PROTEASE, HYDROLASE 
3wz6:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (5)  |   ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3wz8:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (8)  |   ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4n00:A    (ASN66) to   (GLY102)  DISCOVERY OF 7-THP CHROMANS: BACE1 INHIBITORS THAT REDUCE A-BETA IN THE CNS  |   ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5bmt:B    (THR46) to   (SER103)  CRYSTAL STRUCTURE OF AN UNCHARACTERIZED PROTEIN (PARMER_03598) FROM PARABACTEROIDES MERDAE ATCC 43184 AT 1.50 A RESOLUTION  |   IMMUNOGLOBULIN-LIKE FOLD, STRUCTURAL GENOMICS, JOINT CENTER FOR STRUCTURAL GENOMICS, JCSG, PROTEIN STRUCTURE INITIATIVE, PSI- BIOLOGY, UNKNOWN FUNCTION 
1w6h:B     (ASP4) to    (PRO43)  NOVEL PLASMEPSIN II-INHIBITOR COMPLEX  |   MALARIA, DRUG, ASPARTIC PROTEASE, PLASMEPSIN, HYDROLASE, GLYCOPROTEIN 
1w6i:C     (ASN3) to    (PRO43)  PLASMEPSIN II-PEPSTATIN A COMPLEX  |   MALARIA, DRUG, ASPARTIC PROTEASE, PLASMEPSIN, GLYCOPROTEIN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1wkr:A     (ALA1) to    (GLY41)  CRYSTAL STRUCTURE OF ASPARTIC PROTEINASE FROM IRPEX LACTEUS  |   HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1xdh:A     (ASN3) to    (PRO43)  STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH PEPSTATIN A  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1xe5:A     (ASN3) to    (PRO43)  STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1xe5:B     (ASP4) to    (PRO43)  STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1xe6:A     (ASN3) to    (PRO43)  STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5clm:A     (ASN5) to    (GLY41)  1,4-OXAZINE BACE1 INHIBITORS  |   BACE1 PROTEASE INHIBITOR, ORALLY BIOAVAILABLE, BRAIN PENETRANT, PROTEROS BIOSTRUCTURES GMBH, HYDROLASE 
1ls5:A     (ASN3) to    (PRO43)  CRYSTAL STRUCTURE OF PLASMEPSIN IV FROM P. FALCIPARUM IN COMPLEX WITH PEPSTATIN A  |   EUKARYOTIC ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1ls5:B     (ASP4) to    (PRO43)  CRYSTAL STRUCTURE OF PLASMEPSIN IV FROM P. FALCIPARUM IN COMPLEX WITH PEPSTATIN A  |   EUKARYOTIC ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2zht:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF BACE1 AT PH 4.5  |   PH 4.5, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
2zhu:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF BACE1 AT PH 5.0  |   PH 5.0, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
2zhv:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF BACE1 AT PH 7.0  |   PH 7.0, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
1m43:B     (ASN3) to    (PRO43)  CRYSTAL STRUCTURE OF PMII IN COMPLEX WITH PEPSTATIN A TO 2.4 A  |   PLASMEPSIN II, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2zjh:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-(1-BENZYL-PIPERIDIN-4-YL)-4-MERCAPTO-BUTYRAMIDE  |   BACE1, SMALL-MOLECULE INHIBITOR, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
2zjl:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-BROMO-2,3-DIMETHOXY-BENZYL)-PIPERIDIN- 4-YL]-4-MERCAPTO-BUTYRAMIDE  |   BACE1, SMALL-MOLECULE INHIBITOR, TETHERING, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
2zjn:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)- PIPERIDIN-4-YL]-2-(2-METHYL-4-SULFAMOYL-PHENOXY)-ACETAMIDE  |   BACE1, SMALL-MOLECULE INHIBITOR, FRAGMENT-BASED DISCOVERY, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
1me6:B     (ASN3) to    (PRO43)  CRYSTAL STRUCTURE OF PLASMEPSIN II, AN ASPARTYL PROTEASE FROM PLASMODIUM FALCIPARUM, IN COMPLEX WITH A STATINE-BASED INHIBITOR  |   PROTEIN-LIGAND COMPLEX, HYDROLASE 
3kn0:A    (ASN66) to   (GLY102)  STRUCTURE OF BACE BOUND TO SCH708236  |   BACE1, ALZHEIMER'S, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, DISULFIDE BOND, ENDOPLASMIC RETICULUM, ENDOSOME, GLYCOPROTEIN, GOLGI APPARATUS, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
1mpp:A    (GLY-1) to    (PRO41)  X-RAY ANALYSES OF ASPARTIC PROTEINASES. V. STRUCTURE AND REFINEMENT AT 2.0 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM MUCOR PUSILLUS  |   HYDROLASE(ACID PROTEINASE) 
1y9g:A   (GLU241) to   (ASP292)  CRYSTAL STRUCTURE OF EXO-INULINASE FROM ASPERGILLUS AWAMORI COMPLEXED WITH FRUCTOSE  |   EXO-INULINASE, ASPERGILLUS AWAMORI, GLYCOSIDE HYDROLASE FAMILY 32, CRYSTALLOGRAPHIC STRUCTURE, COMPLEX WITH FRUCTOSE, HYDROLASE 
5dpz:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 31  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
5dq1:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 34  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
5dq4:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 66  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
5dq5:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 209  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
5dr0:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 203  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
5dr1:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 278  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
5dr4:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 231  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
5dr8:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 330  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4pzw:A    (ASN66) to   (GLY102)  SYNTHESIS, CHARACTERIZATION AND PK/PD STUDIES OF A SERIES OF SPIROCYCLIC PYRANOCHROMENE BACE1 INHIBITORS  |   ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4pzx:A    (ASN66) to   (GLY102)  SYNTHESIS, CHARACTERIZATION AND PK/PD STUDIES OF A SERIES OF SPIROCYCLIC PYRANOCHROMENE BACE1 INHIBITORS  |   ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3apr:E     (GLY4) to    (ALA44)  BINDING OF A REDUCED PEPTIDE INHIBITOR TO THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS. IMPLICATIONS FOR A MECHANISM OF ACTION  |   HYDROLASE, ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4azy:A     (ASN5) to    (ALA43)  DESIGN AND SYNTHESIS OF BACE1 INHIBITORS WITH IN VIVO BRAIN REDUCTION OF BETA-AMYLOID PEPTIDES (COMPOUND 10)  |   HYDROLASE, AMINOISOINDOLE, ALZHEIMER'S DISEASE 
4b0q:A     (ASN5) to    (ALA43)  LEAD GENERATION OF BACE1 INHIBITORS BY COUPLING NON-AMIDINE NEW WARHEADS TO A KNOWN BINDING SCAFFOLD  |   HYDROLASE, BACE1 INHIBITORS, LEAD GENERATION, STRUCTURE-BASED DRUG DESIGN 
4b1d:A     (ASN5) to    (ALA43)  NEW AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM RATIONAL DESIGN TO AB-LOWERING IN BRAIN  |   HYDROLASE, LEAD GENERATION, STRUCTURE-BASED DRUG DESIGN, INHIBITOR 
4b1e:A     (ASN5) to    (GLY41)  NEW AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM RATIONAL DESIGN TO AB-LOWERING IN BRAIN  |   HYDROLASE, STRUCTURE-BASED DRUG DESIGN 
3lzy:A     (SER1) to    (PHE44)  CRYSTAL STRUCTURE OF ENDOTHIAPESIN IN COMPLEX WITH XENON  |   PROTEIN-XE COMPLEX, HYDROLASE, B-SECRETASE, ENDOTHIAPEPSIN, ASPARTYL PROTEASE, PROTEASE, ZYMOGEN 
4b70:A     (ASN5) to    (GLY41)  AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN  |   HYDROLASE, HYDROLASE INHIBITOR, LEAD GENERATION, STRUCTURE-BASED DRUG DESIGN 
4b72:A     (ASN5) to    (ALA43)  AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN  |   HYDROLASE, HYDROLASE INHIBITOR, LEAD GENERATION, STRUCTURE-BASED DRUG DESIGN 
2ade:A   (GLY198) to   (PRO253)  CRYSTAL STRUCTURE OF FRUCTAN 1-EXOHYDROLASE IIA FROM CICHORIUM INTYBUS IN COMPLEX WITH FRUCTOSE  |   FIVE FOLD BETA PROPELLER, HYDROLASE 
2aez:A   (PRO203) to   (PRO253)  CRYSTAL STRUCTURE OF FRUCTAN 1-EXOHYDROLASE IIA (E201Q) FROM CICHORIUM INTYBUS IN COMPLEX WITH 1-KESTOSE  |   FIVE FOLD BETA PROPELLER, HYDROLASE 
2aey:A   (GLY198) to   (PRO253)  CRYSTAL STRUCTURE OF FRUCTAN 1-EXOHYDROLASE IIA FROM CICHORIUM INTYBUS IN COMPLEX WITH 2,5 DIDEOXY-2,5-IMMINO-D-MANNITOL  |   FIVE FOLD BETA PROPELLER, HYDROLASE 
5enk:A    (ASN53) to    (GLY89)  COMPOUND 18  |   BACE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5enm:A    (ASN53) to    (GLY89)  COMPOUND 10  |   BACE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3msj:A     (ASN5) to    (GLY41)  STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR  |   PROTEASE, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, AMYLOID PRECURSOR PROTEIN SECRETASES, ASPARTIC ENDOPEPTIDASES, FRAGMENT- BASED DRUG DESIGN, FLUORESCENCE POLARISATION, TRANSMEMBRANE, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3msj:B     (ASN5) to    (GLY41)  STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR  |   PROTEASE, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, AMYLOID PRECURSOR PROTEIN SECRETASES, ASPARTIC ENDOPEPTIDASES, FRAGMENT- BASED DRUG DESIGN, FLUORESCENCE POLARISATION, TRANSMEMBRANE, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3msj:C     (ASN5) to    (GLY41)  STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR  |   PROTEASE, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, AMYLOID PRECURSOR PROTEIN SECRETASES, ASPARTIC ENDOPEPTIDASES, FRAGMENT- BASED DRUG DESIGN, FLUORESCENCE POLARISATION, TRANSMEMBRANE, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3msk:A     (ASN5) to    (GLY41)  FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS  |   PROTEASE, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, AMYLOID PRECURSOR PROTEIN SECRETASES, ASPARTIC ENDOPEPTIDASES, FRAGMENT- BASED DRUG DESIGN, FLUORESCENCE POLARISATION, TRANSMEMBRANE, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5ez3:D   (TRP223) to   (GLY283)  CRYSTAL STRUCTURE ACYL-COA DEHYDROGENASE FROM BRUCELLA MELITENSIS IN COMPLEX WITH FAD  |   SSGCID, DEHYDROGENASE, FAD, STRUCTURAL GENOMICS, SEATTLE STRUCTURAL GENOMICS CENTER FOR INFECTIOUS DISEASE, OXIDOREDUCTASE 
5ezz:A    (ASN66) to   (ALA104)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (4S)-4-[3-(5-CHLORO-3- PYRIDYL)PHENYL]-4-[4-(DIFLUOROMETHOXY)-3-METHYL-PHENYL]-5H-OXAZOL-2- AMINE  |   PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX, HYDROLASE- INHIBITOR COMPLEX 
5f01:A    (ASN66) to   (GLY102)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (1SR,2SR)-2-((R)-2-AMINO- 5,5-DIFLUORO-4-METHYL-5,6-DIHYDRO-4H-1,3-OXAZIN-4-YL)-N-(3- CHLOROQUINOLIN-8-YL)CYCLOPROPANECARBOXAMIDE  |   PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX, HYDROLASE 
3bug:A     (ASN5) to    (GLY41)  BACE-1 COMPLEXED WITH COMPOUND 3  |   ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, BETA-SECRETASE, MEMAPSIN 2, FRAGMENT SCREEN, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, TRANSMEMBRANE, ZYMOGEN 
4r5n:A    (ASN66) to   (GLY102)  8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS  |   ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3ckr:C     (ASN5) to    (ALA43)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR  |   BETA-SECRETASE, ASPARTYL PROTEASE, ALTERNATIVE SPLICING, GLYCOPROTEIN, HYDROLASE, MEMBRANE, TRANSMEMBRANE, ZYMOGEN 
3cms:A    (GLU-1) to    (PRO41)  ENGINEERING ENZYME SUB-SITE SPECIFICITY: PREPARATION, KINETIC CHARACTERIZATION AND X-RAY ANALYSIS AT 2.0-ANGSTROMS RESOLUTION OF VAL111PHE SITE-MUTATED CALF CHYMOSIN  |   HYDROLASE, ACID PROTEINASE 
3nvk:I     (MET1) to    (ILE50)  STRUCTURAL BASIS FOR SUBSTRATE PLACEMENT BY AN ARCHAEAL BOX C/D RIBONUCLEOPROTEIN PARTICLE  |   NOP DOMAIN KINK TURN METHYL TRANSFERASE, RIBOSOME BIOGENESIS SPLICEOSOME BIOGENESIS, TRANSFERASE-RNA COMPLEX 
3nvm:B     (MET1) to    (ASN52)  STRUCTURAL BASIS FOR SUBSTRATE PLACEMENT BY AN ARCHAEAL BOX C/D RIBONUCLEOPROTEIN PARTICLE  |   NOP DOMAIN, METHYLTRANSFERASE, RIBOSOME BIOGENESIS, SPLICEOSOME BIOGENESIS, TRANSFERASE 
4rrn:A    (ASN66) to   (GLY102)  8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS  |   ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4cku:A     (ASN3) to    (PRO43)  THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR  |   HYDROLASE, MALARIA, DRUG DESIGN 
4cku:B     (ASN3) to    (PRO43)  THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR  |   HYDROLASE, MALARIA, DRUG DESIGN 
4cku:C     (ASP4) to    (PRO43)  THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR  |   HYDROLASE, MALARIA, DRUG DESIGN 
4cku:D     (ASP4) to    (PRO43)  THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR  |   HYDROLASE, MALARIA, DRUG DESIGN 
4cku:E     (ASP4) to    (PRO43)  THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR  |   HYDROLASE, MALARIA, DRUG DESIGN 
4cku:F     (GLU7) to    (PRO43)  THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR  |   HYDROLASE, MALARIA, DRUG DESIGN 
4ryc:A    (ASN-1) to    (PRO41)  RENIN IN COMPLEXED WITH 4-METHOXY-3-(3-METHOXYPROPOXY)-N-{[(3S,4S)-4- {[(4-METHYLPHENYL)SULFONYL]AMINO}PYRROLIDIN-3-YL]METHYL}-N-(PROPAN-2- YL)BENZAMIDE INHIBITOR  |   HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4cms:A    (GLU-1) to    (PRO41)  X-RAY ANALYSES OF ASPARTIC PROTEINASES IV. STRUCTURE AND REFINEMENT AT 2.2 ANGSTROMS RESOLUTION OF BOVINE CHYMOSIN  |   HYDROLASE (ACID PROTEINASE) 
4ryg:A     (ILE5) to    (PRO41)  RENIN IN COMPLEXED WITH N-({(3S,4S)-4-[(BENZYLSULFONYL) AMINO]PYRROLIDIN-3-YL}METHYL)-4-METHOXY-3-(3-METHOXYPROPOXY)-N- (PROPAN-2-YL)BENZAMIDE INHIBITOR  |   HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4s1g:A    (ASN71) to   (PRO113)  REIN IN COMPLEX WITH (S)-1-(3-FLUORO-5-(((S)-1-PHENYLETHYL)CARBAMOYL) BENZYL)-4-ISOPROPYL-4-METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM  |   ASPARTIC PROTEASE, BLOOD PREASURE, ANGIOTENSINOGEN, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
4s1g:B    (ASN71) to   (PRO113)  REIN IN COMPLEX WITH (S)-1-(3-FLUORO-5-(((S)-1-PHENYLETHYL)CARBAMOYL) BENZYL)-4-ISOPROPYL-4-METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM  |   ASPARTIC PROTEASE, BLOOD PREASURE, ANGIOTENSINOGEN, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
3oag:C    (VAL10) to    (PRO47)  DESIGN AND OPTIMIZATION OF NEW PIPERIDINES AS RENIN INHIBITORS  |   HYDROLASE, PROTEASE, GLYCOSILATION, BLOOD, HYDROLASE - HYDROLASE INHIBITOR COMPLEX 
3d91:A     (ASN5) to    (PRO47)  HUMAN RENIN IN COMPLEX WITH REMIKIREN  |   RENIN, REMIKIREN, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, SECRETED, ZYMOGEN 
3d91:B     (ASN5) to    (PRO47)  HUMAN RENIN IN COMPLEX WITH REMIKIREN  |   RENIN, REMIKIREN, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, SECRETED, ZYMOGEN 
3oot:A     (THR0) to    (PRO41)  CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES  |   RENIN HUMAN, ASPARTYL PROTEASE, RENIN INHIBITION, HYPERTENSION, HYDROLASE 
4d85:A     (ASN7) to    (GLY43)  CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BVI151  |   BETA-SECRETASE, MEMAPSIN2, BACE1, ASPARTIC PROTEINASE, ALZHEIMER'S DISEASE, ENZYME INHIBITOR COMPLEX, STRUCTURE-BASED DRUG DESIGN, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4d88:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXQ490  |   BETA-SECRETASE, MEMAPSIN2, BACE1, ASPARTIC PROTEINASE, ALZHEIMER'S DISEASE, ENZYME INHIBITOR COMPLEX, STRUCTURE-BASED DRUG DESIGN, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4d89:A    (ASN53) to    (GLY89)  CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552, DERIVED FROM A SOAKING EXPERIMENT  |   BETA-SECRETASE, MEMAPSIN2, BACE1, ASPARTIC PROTEINASE, ALZHEIMER'S DISEASE, ENZYME INHIBITOR COMPLEX, STRUCTURE-BASED DRUG DESIGN, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3oqk:A     (THR0) to    (PRO41)  CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES  |   RENIN HUMAN, ASPARTYL PROTEASE, RENIN INHIBITION, HYPERTENSION, HYDROLASE 
5hct:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH BIACYLHYDRAZONE  |   HYDROLASE, INHIBITION 
5hd0:A    (ASN66) to   (GLY102)  BACE-1 IN COMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUOROPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3,4- D]PYRIMIDIN-2-IMINIUM  |   ASPARTYL PROTEASE, BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1, BETA-SITE APP CLEAVING ENZYME 1, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5hdu:A    (ASN66) to   (GLY102)  BACE-1 INCOMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUORO-4-METHOXYPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3, 4-D]PYRIMIDIN-2-IMINIUM  |   ALZHEIMER'S, ASPARTYL PROTEASE, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3own:A     (ASN2) to    (PRO44)  POTENT MACROCYCLIC RENIN INHIBITORS  |   RENIN, PROTEASE, ASPARTYL PROTEASE, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3own:B     (ASN2) to    (PRO44)  POTENT MACROCYCLIC RENIN INHIBITORS  |   RENIN, PROTEASE, ASPARTYL PROTEASE, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4dh6:A     (ASN5) to    (GLY41)  STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH (2R)-N-((2S,3R)- 1-(BENZO[D][1,3]DIOXOL-5-YL)-3-HYDROXY-4-((S)-6'-NEOPENTYL-3',4'- DIHYDROSPIRO[CYCLOBUTANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YLAMINO) BUTAN-2-YL)-2-METHOXYPROPANAMIDE  |   BACE-1, BETA-SECRETASE, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4di2:B     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE INHIBITOR 37  |   MEMAPSIN-2, ALZHEIMER'S DISEASE, PROTEASE, BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1, APP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4dpf:A    (ASN53) to    (GLY89)  BACE-1 IN COMPLEX WITH A HEA-MACROCYCLIC TYPE INHIBITOR  |   BACE1, ASP2, BACE, MACROCYCLE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4dpi:A    (ASN53) to    (GLY89)  BACE-1 IN COMPLEX WITH HEA-MACROCYCLIC INHIBITOR, MV078512  |   BACE1, ASP2, BACE, MACROCYCLE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pb5:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pbd:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pbz:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pcw:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pep:A     (ILE1) to    (PRO41)  REVISED 2.3 ANGSTROMS STRUCTURE OF PORCINE PEPSIN. EVIDENCE FOR A FLEXIBLE SUBDOMAIN  |   HYDROLASE (ACID PROTEINASE) 
3pgi:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pi0:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pld:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pm4:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pmu:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pmy:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3prs:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH RITONAVIR  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3psy:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION  |   HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pww:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH SAQUINAVIR  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3q4b:A    (ASN-1) to    (PRO41)  CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS  |   ASPARTATE PROTEASE, HYPERTENSION, RENIN EXPRESSION, RENIN INHIBITOR, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, GLYCOPROTEIN, MEMBRANE, PROTEASE, SECRETED, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3q5h:A    (ASN-1) to    (PRO41)  CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS  |   ASPARTATE PROTEASE, HYPERTENSION, RENIN EXPRESSION, RENIN INHIBITOR, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, MEMBRANE, PROTEASE, SECRETED, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
3q5h:B     (THR0) to    (PRO41)  CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS  |   ASPARTATE PROTEASE, HYPERTENSION, RENIN EXPRESSION, RENIN INHIBITOR, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, MEMBRANE, PROTEASE, SECRETED, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
3q6y:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH A PYRROLIDINE BASED INHIBITOR  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4ewo:A    (ASN53) to    (GLY89)  DESIGN AND SYNTHESIS OF POTENT HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS  |   BACE, BETA-SECRETASE, STATINE, INHIBITOR, ASPARTYL PROTEASE, GLYCOPROTEIN, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
3qrv:A     (ALA0) to    (PRO41)  CRYSTAL STRUCTURE OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM  |   ASPARTIC PROTEASE, MALARIA, HYDROLASE 
3qrv:B     (THR5) to    (PRO41)  CRYSTAL STRUCTURE OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM  |   ASPARTIC PROTEASE, MALARIA, HYDROLASE 
3qs1:B     (ASP2) to    (PRO41)  CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM  |   ASPARTIC PROTEASE, MALARIA, KNI, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3qs1:C     (GLY1) to    (PRO41)  CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM  |   ASPARTIC PROTEASE, MALARIA, KNI, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3qs1:D     (GLY1) to    (PRO41)  CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM  |   ASPARTIC PROTEASE, MALARIA, KNI, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3r1g:B    (ASN66) to   (GLY102)  STRUCTURE BASIS OF ALLOSTERIC INHIBITION OF BACE1 BY AN EXOSITE- BINDING ANTIBODY  |   ASPARTAL PROTEASE, PROTEIN BINDING 
4fm7:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF BACE WITH COMPOUND 14G  |   ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4frj:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOOXAZOLINE XANTHENE 9L  |   MEMBRANE PROTEIN, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, HYDROLASE- INHIBITOR COMPLEX 
4frs:A    (ASN66) to   (GLY102)  STRUCTURE OF BACE IN COMPLEX WITH (S)-4-(3-CHLORO-5-(5-(PROP-1-YN-1- YL)PYRIDIN-3-YL)THIOPHEN-2-YL)-1,4-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN- 2(1H)-IMINIUM  |   ALZHEIMER'S, ASPARTYL PROTEASE, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4fs4:A    (ASN66) to   (GLY102)  STRUCTURE OF BACE BOUND TO (S)-4-(3'-METHOXY-[1,1'-BIPHENYL]-3-YL)-1, 4-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM  |   BACE1, ALZHEIMERS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gj5:A     (THR0) to    (PRO41)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AMQ838 (COMPOUND 5)  |   RENIN INHIBITOR, PHARMACOPHORE SEARCH, TRANS-3,4-DISUBSTITUTED PYRROLIDINE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gj5:B    (ASN-1) to    (PRO41)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AMQ838 (COMPOUND 5)  |   RENIN INHIBITOR, PHARMACOPHORE SEARCH, TRANS-3,4-DISUBSTITUTED PYRROLIDINE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gj8:A    (ASN-1) to    (PRO41)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH PKF909-724 (COMPOUND 3)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gj8:B     (THR1) to    (PRO41)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH PKF909-724 (COMPOUND 3)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gja:A     (ILE5) to    (PRO41)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYL747 (COMPOUND 5)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gjc:A     (ILE5) to    (PRO41)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCH965 (COMPOUND 9)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gjc:B    (ASN-1) to    (PRO41)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCH965 (COMPOUND 9)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gjd:A     (ILE5) to    (PRO41)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BGQ311 (COMPOUND 12)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gmi:A     (ASN5) to    (GLY41)  BACE-1 IN COMPLEX WITH HEA-TYPE MACROCYCLIC INHIBITOR, MV078571  |   BACE-1, ASP2, BACE, MACROCYCLE, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5koq:A     (THR6) to    (PRO47)  DISCOVERY OF TAK-272: A NOVEL, POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR  |   PROTEIN-INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5koq:B    (ILE11) to    (PRO47)  DISCOVERY OF TAK-272: A NOVEL, POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR  |   PROTEIN-INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5kos:A     (ASN5) to    (PRO47)  DISCOVERY OF TAK-272: A NOVEL, POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR  |   PROTEIN-INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5oyq:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 1  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oyr:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 2  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oys:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 3  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oyt:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 4  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oyu:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 5  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oyv:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 6  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oyw:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 7  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oyx:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 8  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oyy:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 9  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oyz:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 10  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz0:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 11  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz1:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 12  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz2:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 13  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz3:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 14  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz5:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 16  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz6:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 17  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz7:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 18  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz8:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 19  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz9:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 20  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oza:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 21  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozb:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 22  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozc:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 23  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozd:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 24  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oze:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 25  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozf:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 26  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozg:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 27  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozh:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 28  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozi:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 29  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozk:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 31  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozl:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 32  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozm:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 33  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozn:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 34  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozo:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 35  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozp:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 36  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozq:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 37  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozr:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 38  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozs:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 39  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozt:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 40  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozu:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 41  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozv:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 42  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozw:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 43  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozx:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 44  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozy:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 45  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozz:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 46  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p00:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 47  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p02:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 49  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p03:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 50  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p04:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 51  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p06:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 53  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p07:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 54  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p08:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 55  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p09:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 56  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0b:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 58  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0c:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 59  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0d:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 60  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0f:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 62  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0g:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 63  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0h:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 64  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0i:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 65  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0j:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 66  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0k:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 67  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0l:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 68  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0m:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 69  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0n:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 70  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0o:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 71  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0p:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 72  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0q:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 73  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0r:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 74  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0s:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 75  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0t:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 76  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0u:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 77  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0v:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 78  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0x:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 80  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0y:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 81  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0z:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 82  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p10:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 83  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p11:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 84  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p12:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 85  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p14:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 87  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p15:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 88  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p16:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 89  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p17:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 90  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p18:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 91  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p19:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 92  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1a:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 93  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1b:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 94  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1d:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 96  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1e:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 97  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1f:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 98  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1g:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 99  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1i:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 101  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1j:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 102  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1k:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 103  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1l:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 104  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1m:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 105  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1p:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 108  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1r:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 110  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1s:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 111  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1u:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 113  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1w:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 115  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1x:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 116  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1y:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 117  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1z:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 118  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p20:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 119  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p22:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 120  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p23:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 121  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p24:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 122  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p25:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 123  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p26:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 124  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p27:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 125  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p28:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 126  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p29:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 127  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2b:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 129  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2d:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 131  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2f:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 133  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2g:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 134  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2h:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 135  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2k:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 138  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2l:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 139  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2m:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 140  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2n:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 141  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2o:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 142  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2q:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 143  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2r:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 144  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2t:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 146  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2u:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 147  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2v:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 148  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2w:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 149  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2x:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 150  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2z:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 152  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p30:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 153  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p31:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 154  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p32:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 155  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p33:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 156  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p34:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 157  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p35:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 158  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p36:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 159  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p37:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 160  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p38:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 161  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3b:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 164  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3c:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 165  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3d:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 166  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3e:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 167  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3g:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 169  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3i:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 171  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3j:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 172  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3k:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 173  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3l:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 174  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3m:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 175  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3n:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 176  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3o:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 177  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3p:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 178  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3q:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 179  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3r:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 180  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3s:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 181  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3t:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 182  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3u:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 183  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3v:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 184  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3w:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 185  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3x:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 186  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3y:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 187  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3z:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 188  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p40:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 189  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p41:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 190  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p42:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 191  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p43:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 192  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p44:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 193  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p45:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 194  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p46:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 195  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p47:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 196  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p48:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 197  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p49:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 198  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4a:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 199  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4b:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 200  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4c:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 201  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4d:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 202  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4e:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 203  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4f:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 204  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4g:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 205  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4h:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 206  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4i:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 207  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4j:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 208  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4k:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 209  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4l:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 210  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4m:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 211  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4o:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 213  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4p:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 214  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4q:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 215  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4r:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 216  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4s:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 217  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4t:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 218  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4v:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 220  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4w:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 221  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4y:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 223  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4z:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 224  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p53:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 228  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p54:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 229  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p55:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 230  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p56:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 231  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p58:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 233  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p59:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 234  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5a:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 235  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5c:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 237  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5d:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 238  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5e:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 239  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5f:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 240  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5g:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 241  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5h:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 242  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5i:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 243  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5j:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 244  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5k:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 245  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5l:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 246  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5m:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 247  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5n:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 248  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5o:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 249  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5q:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 251  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5r:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 252  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5s:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 253  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5t:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 254  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5u:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 255  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5v:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 256  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5w:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 257  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5x:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 258  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5y:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 259  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5z:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 260  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p61:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 262  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p62:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 263  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p63:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 264  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p64:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 265  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p65:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 266  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p66:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 267  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p68:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 269  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6a:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 271  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6c:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 273  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6d:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 274  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6e:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 275  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6g:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 277  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6h:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 278  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6i:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 279  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6j:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 280  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6k:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 281  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6l:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 282  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6m:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 283  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6n:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 284  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6o:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 285  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6p:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 286  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6q:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 287  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6r:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 288  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6s:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 289  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6t:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 290  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6u:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 291  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6v:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 292  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6w:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 293  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6x:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 294  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6y:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 295  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6z:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 296  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p70:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 297  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p71:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 298  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p72:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 299  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p75:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 302  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p76:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 303  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p77:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 304  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p78:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 305  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7a:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 307  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7b:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 308  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7c:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 309  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7d:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 310  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7e:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 311  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7i:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 315  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7j:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 316  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7m:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 319  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7n:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 320  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7o:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 321  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7p:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 322  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7q:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 323  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7r:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 324  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7t:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 326  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7u:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 327  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7v:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 328  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7w:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 329  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7x:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 330  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7y:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 331  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7z:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 332  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p80:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 333  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p81:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 334  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p82:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 335  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p83:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 336  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p84:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 337  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p85:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 338  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p86:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 339  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p87:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 340  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p88:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 341  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p89:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 342  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8a:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 343  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8b:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 344  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8c:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 345  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8d:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 346  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8e:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 347  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8f:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 348  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8h:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 350  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8j:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 352  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8k:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 353  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8l:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 354  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8m:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 355  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8n:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 356  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8o:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 357  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8p:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 358  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8r:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 360  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8s:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 361  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8t:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 362  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8u:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 363  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8v:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 364  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5sxn:A     (ASN5) to    (PRO47)  STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5sxn:B     (ASN5) to    (PRO47)  STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5sy3:A     (ASN5) to    (PRO47)  STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5sz9:A     (THR6) to    (PRO47)  STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5sz9:B     (THR6) to    (PRO47)  STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5t4s:B    (ILE11) to    (PRO47)  NOVEL APPROACH OF FRAGMENT-BASED LEAD DISCOVERY APPLIED TO RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
6apr:E     (GLY4) to    (ALA44)  STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3rsx:A     (ASN5) to    (GLY41)  STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 6-(THIOPHEN-3- YL)QUINOLIN-2-AMINE  |   ASPARTIC PROTEASE, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1apt:E     (ALA1) to    (PHE42)  CRYSTALLOGRAPHIC ANALYSIS OF A PEPSTATIN ANALOGUE BINDING TO THE ASPARTYL PROTEINASE PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4i0j:A    (ASN66) to   (GLY102)  SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS  |   BACE ASP PROTEASE, HYDROLYSIS,, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2c62:A    (ALA62) to    (PRO98)  CRYSTAL STRUCTURE OF THE HUMAN TRANSCRIPTION COFACTOR PC4 IN COMPLEX WITH SINGLE-STRANDED DNA  |   TRANSCRIPTION COFACTOR, SINGLE-STRANDED DNA, PROTEIN-DNA COMPLEX, DNA UNWINDING, ACTIVATOR, DNA-BINDING, NUCLEAR PROTEIN, PHOSPHORYLATION, TRANSCRIPTION, TRANSCRIPTION REGULATION 
2c62:B    (ALA62) to    (PRO98)  CRYSTAL STRUCTURE OF THE HUMAN TRANSCRIPTION COFACTOR PC4 IN COMPLEX WITH SINGLE-STRANDED DNA  |   TRANSCRIPTION COFACTOR, SINGLE-STRANDED DNA, PROTEIN-DNA COMPLEX, DNA UNWINDING, ACTIVATOR, DNA-BINDING, NUCLEAR PROTEIN, PHOSPHORYLATION, TRANSCRIPTION, TRANSCRIPTION REGULATION 
4y39:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 75  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y3f:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 78  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y3g:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 285  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y3z:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 41  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y41:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 112  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y4g:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B53  |   FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE 
4y4u:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 14  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y4x:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 51  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y50:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 81  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
1e81:E    (SER-2) to    (PHE41)  ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD61395  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4yd4:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 227  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4yd7:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 255  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
2v0z:C    (ASN-1) to    (PRO41)  CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 10 (ALISKIREN)  |   GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES 
2v0z:O     (ILE5) to    (PRO41)  CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 10 (ALISKIREN)  |   GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES 
1flh:A     (ASP2) to    (PRO41)  CRYSTAL STRUCTURE OF HUMAN UROPEPSIN AT 2.45 A RESOLUTION  |   ACID PROTEINASE, HYDROLASE 
4ze6:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B39  |   FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE 
2vnm:A    (ASN66) to   (GLY102)  HUMAN BACE-1 IN COMPLEX WITH 3-(1,1-DIOXIDOTETRAHYDRO-2H-1, 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)BENZAMIDE  |   HYDROLASE, ALTERNATIVE SPLICING, BETA-SITE APP CLEAVING ENZYME, BETA-SECRETASE, ASPARTYL PROTEASE, ASP-2, BACE-1, ZYMOGEN, PROTEASE, MEMBRANE, MEMAPSIN-2, GLYCOPROTEIN, TRANSMEMBRANE 
2g1r:A     (SER3) to    (PRO42)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g1r:B     (SER3) to    (PRO42)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
1st8:A   (PRO203) to   (PRO253)  CRYSTAL STRUCTURE OF FRUCTAN 1-EXOHYDROLASE IIA FROM CICHORIUM INTYBUS  |   FIVE FOLD BETA PROPELLER, HYDROLASE 
2wed:A     (ALA1) to    (PHE42)  ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE MACROCYCLIC INHIBITOR:METHYL[CYCLO-7[(2R)- ((N-VALYL)AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2- PHENYLETHOXY)PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE], SODIUM SALT  |   PENICILLOPEPSIN, MACROCYCLIC INHIBITOR, HYDROLASE 
1i4e:A   (LEU217) to   (LYS263)  CRYSTAL STRUCTURE OF THE CASPASE-8/P35 COMPLEX  |   COVALENT COMPLEX PROTEASE-INHIBITOR, APOPTOSIS-HYDROLASE COMPLEX 
1uh9:A     (GLY4) to    (ALA44)  CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 7.0  |   PEPSIN, ASPARTIC PROTEINASE, HYDROLASE 
3wb5:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH (6S)-2-AMINO-3,6- DIMETHYL-6-[(1R,2R)-2-PHENYLCYCLOPROPYL]-3,4,5,6-TETRAHYDROPYRIMIDIN- 4-ONE  |   PROTEASE 2, ASP2, MEMBRANE-ASSOCIATED ASPARTIC PROTEASE 2, MEMAPSIN- 2, HYDROLASE 
2jjj:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.  |   ACID PROTEINASE, ASPARTYL PROTEASE, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3zov:A    (ASN66) to   (GLY102)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND  |   HYDROLASE 
1lee:A     (ASP4) to    (PRO43)  CRYSTAL STRUCTURE OF PLASMEPSIN FROM P. FALCIPARUM IN COMPLEX WITH INHIBITOR RS367  |   PLASMEPSIN, ASPARTIC PROTEASE, PLASMODIUM FALCIPARUM, HYDROLASE 
3k1w:A     (ASN5) to    (PRO47)  NEW CLASSES OF POTENT AND BIOAVAILABLE HUMAN RENIN INHIBITORS  |   RENIN, PROTEASE, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, SECRETED, ZYMOGEN 
2zji:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(2,6-DIMETHOXY-BENZYL)-PIPERIDIN-4-YL]-4-MERCAPTO-BUTYRAMIDE  |   BACE1, SMALL-MOLECULE INHIBITOR, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
4acu:A     (ASN5) to    (ALA43)  AMINOIMIDAZOLES AS BACE-1 INHIBITORS. X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 14  |   HYDROLASE, ALZHEIMER'S DISEASE 
4acx:A     (ASN5) to    (ALA43)  AMINOIMIDAZOLES AS BACE-1 INHIBITORS. X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 23  |   HYDROLASE, ALZHEIMER'S DISEASE 
1y4w:A   (GLU241) to   (ASP292)  CRYSTAL STRUCTURE OF EXO-INULINASE FROM ASPERGILLUS AWAMORI IN SPACEGROUP P21  |   EXO-INULINASE, ASPERGILLUS AWAMORI, GLYCOSIDE HYDROLASE FAMILY 32, CRYSTALLOGRAPHIC STRUCTURE, NATIVE STRUCTURE, HYDROLASE 
3l5f:A    (ASN66) to   (GLY102)  STRUCTURE OF BACE BOUND TO SCH736201  |   BACE1, ALZHEIMERS, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, DISULFIDE BOND, ENDOPLASMIC RETICULUM, ENDOSOME, GLYCOPROTEIN, GOLGI APPARATUS, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
5dq2:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 48  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
5dr3:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 333  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
5dr7:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 311  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4apr:E     (GLY4) to    (ALA44)  STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4q1n:A    (ASN-1) to    (PRO41)  STRUCTURE-BASED DESIGN OF 4-HYDROXY-3,5-SUBSTITUTED PIPERIDINES AS DIRECT RENIN INHIBITORS  |   ASPARTIC PROTEASE, ANGIOTENSIN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4q1n:B    (ASN-1) to    (PRO41)  STRUCTURE-BASED DESIGN OF 4-HYDROXY-3,5-SUBSTITUTED PIPERIDINES AS DIRECT RENIN INHIBITORS  |   ASPARTIC PROTEASE, ANGIOTENSIN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4b78:A     (ASN5) to    (ALA43)  AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN  |   HYDROLASE, HYDROLASE INHIBITOR, LEAD GENERATION, STRUCTURE-BASED DRUG DESIGN 
3ckp:C     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR  |   BETA-SECRETASE, ASPARTYL PROTEASE, ALTERNATIVE SPLICING, GLYCOPROTEIN, HYDROLASE, MEMBRANE, TRANSMEMBRANE, ZYMOGEN 
4d83:A     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436, DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT  |   BETA-SECRETASE, MEMAPSIN2, BACE1, ASPARTIC PROTEINASE, ALZHEIMER'S DISEASE, ENZYME INHIBITOR COMPLEX, STRUCTURE-BASED DRUG DESIGN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4d83:B     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436, DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT  |   BETA-SECRETASE, MEMAPSIN2, BACE1, ASPARTIC PROTEINASE, ALZHEIMER'S DISEASE, ENZYME INHIBITOR COMPLEX, STRUCTURE-BASED DRUG DESIGN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4d83:C     (ASN5) to    (GLY41)  CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436, DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT  |   BETA-SECRETASE, MEMAPSIN2, BACE1, ASPARTIC PROTEINASE, ALZHEIMER'S DISEASE, ENZYME INHIBITOR COMPLEX, STRUCTURE-BASED DRUG DESIGN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pll:A     (SER1) to    (PHE44)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gj6:A    (ASN-1) to    (PRO41)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYZ832 (COMPOUND 6A)  |   RENIN INHIBITOR, PHARMACOPHORE SEARCH, TRANS-3,4-DISUBSTITUTED PYRROLIDINE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gj6:B     (THR0) to    (PRO41)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYZ832 (COMPOUND 6A)  |   RENIN INHIBITOR, PHARMACOPHORE SEARCH, TRANS-3,4-DISUBSTITUTED PYRROLIDINE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5kr8:A    (ASN53) to    (GLY89)  (4~{S},6~{S})-4-[2,4-BIS(FLUORANYL)PHENYL]-6-(3,5-DIMETHYL-1,2-OXAZOL- 4-YL)-4-METHYL-5,6-DIHYDRO-1,3-THIAZIN-2-AMINE (COMPOUND 5) BOUND TO BACE1  |   BACE-1, SMALL MOLECULE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5oz4:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 15  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozj:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 30  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p01:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 48  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p05:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 52  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0a:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 57  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0e:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 61  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0w:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 79  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p13:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 86  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1c:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 95  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1h:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 100  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1n:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 106  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1o:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 107  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1q:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 109  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1t:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 112  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1v:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 114  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2a:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 128  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2c:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 130  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2e:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 132  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2i:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 136  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2j:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 137  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2s:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 145  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2y:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 151  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p39:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 162  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3a:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 163  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3f:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 168  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3h:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 170  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4n:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 212  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4u:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 219  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4x:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 222  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p50:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 225  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p51:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 226  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p52:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 227  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p57:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 232  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5b:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 236  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5p:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 250  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p60:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 261  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p67:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 268  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p69:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 270  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6b:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 272  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6f:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 276  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p73:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 300  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p74:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 301  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p79:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 306  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7f:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 312  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7g:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 313  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7h:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 314  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7k:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 317  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7l:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 318  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7s:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 325  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8g:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 349  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8i:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 351  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8q:A     (SER1) to    (PHE44)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 359  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5sy2:B    (ILE11) to    (PRO47)  STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX